Skip to main
AUPH

Aurinia Pharmaceuticals (AUPH) Stock Forecast & Price Target

Aurinia Pharmaceuticals (AUPH) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Aurinia Pharmaceuticals is projected to experience substantial revenue growth, with risk-adjusted product revenues expected to rise from $243.7 million in 2025 to $932.3 million by 2033. The anticipated launch of aritinercept is forecasted to generate risk-adjusted revenue of $15.4 million in 2030, increasing significantly to $281.6 million by 2033, assuming a 20% probability of launch and a 15% peak penetration rate. Furthermore, the upcoming 2024 ACR LN guideline is expected to materially enhance the market position of LUPKYNIS, catalyzing a new phase of growth for the product starting in 2027.

Bears say

Aurinia Pharmaceuticals faces challenges due to limited therapeutic options and high competition within the autoimmune disease treatment market, impacting its revenue growth potential. Additionally, the company's reliance on a single product, LUPKYNIS, raises concerns regarding sustainability and market penetration, especially as it faces upcoming patent expirations. Lastly, the development pipeline, including AUR200, may not sufficiently mitigate risks associated with dependency on existing products or lead to timely commercial success.

Aurinia Pharmaceuticals (AUPH) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aurinia Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aurinia Pharmaceuticals (AUPH) Forecast

Analysts have given Aurinia Pharmaceuticals (AUPH) a Buy based on their latest research and market trends.

According to 4 analysts, Aurinia Pharmaceuticals (AUPH) has a Buy consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aurinia Pharmaceuticals (AUPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.